This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 17.78% and 7.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
by Zacks Equity Research
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -24.32% and 4.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Avidity Biosciences, Inc. (RNA) a New Buy Stock
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Avidity Biosciences, Inc. (RNA) Could Rally 242%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Avidity Biosciences, Inc. (RNA) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Avidity Biosciences, Inc. (RNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.